Researchers uncover potentially promising therapeutic combination for renal cell carcinoma

(Beth Israel Deaconess Medical Center) Investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival.